超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

Chronix Biomedical,  
Chronix生物醫學公司是一家分子診斷學公司，主要開發癌癥的血液測試，包括伴隨診斷和用于檢測微小殘留病的測試。Chronix生物醫學公司正在準備通過它自己的CLIA認證實驗室提供它的開創性的測試。該公司的最初產品是將會被癌癥治療中心和腫瘤學家在治療癌癥病人的時候使用的一種測試。Chronix生物醫學公司是一家私營公司，總部設在加利福尼亞州的圣何塞，實驗室設在德國哥廷根以及美國南達科他州的布魯金斯。它是第一家對無細胞DNA使用下一代測序技術的公司。該公司擁有兩個檢測無細胞DNA和RNA的已批準的專利，以及使用下一代測序技術用于檢測乳腺癌、前列腺癌和結直腸癌的4個正在申請的專利。

Chronix Biomedical, Inc. is a molecular diagnostics company developing blood tests primarily for monitoring minimal residual disease (MRD) in cancer patients. Chronix will offer its pioneering tests through its own CLIA certified laboratories expected to open in 2015. The value proposition of the Chronix MRD test is that it:
1) Reduces costs by saving money on unnecessary treatments and more importantly treating cancer recurrences earlier in patients.
2) Improves quality in healthcare by treating a patients recurrences of cancer as earlier as possible. In addition, it eliminates unnecessary treatments to patients.
3) Increases access to healthcare because a patient can have their blood drawn at any blood-drawing station or in their physician's office and sent to the Chronix laboratory.
Chronix is privately held with headquarters in San Jose, California, and laboratories in G?ttingen, Germany and Brookings, South Dakota.